ArticleThe Lancet regional health. Europe2023
Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Pooled it
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- Inflammasome Dynamics in the High-Risk Clone ST235 with Altered Pyoverdine Structures.International journal of molecular sciences · 2026Article
- Evaluation of carbapenem inactivation method-based phenotypic assays for the detection of GES-type carbapenemases in Enterobacterales,Journal of clinical microbiology · 2026Article
- Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Prevalence and genotypic distribution of virulence factor genes and antibiotic susceptibility profiles in clinicalMicrobiology spectrum · 2026Article
- Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Emergence of KPC-producingAntimicrobial agents and chemotherapy · 2026Article
- Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes.The Journal of antimicrobial chemotherapy · 2026Article
- Trojan Horses: Conjugating Siderophores and Antibiotics-A New Approach to TreatingMicroorganisms · 2026Review
- Emergence of outbreak-driving high-riskMicrobial genomics · 2026Article
- Article
- Identification and functional insights into new phage tail-like bacteriocins targetingMicrobiology spectrum · 2026Article
- AMR-GNN: a multi-representation graph neural network framework to enable genomic antimicrobial resistance prediction.Nature communications · 2026Article
- NDM-producing Multidrug-resistantInfection & chemotherapy · 2026Article
- Epidemiological insights into Haemophilus influenzae and Pseudomonas aeruginosa persistent colonization in non-cystic fibrosis bronchiectasis patients: a longitudinal and multicenter study.Respiratory research · 2026Article
- Multidrug-resistant gram-negative bacteria in Spanish ICU patients: clinical and microbiological characterization (MURAN-UCI Project).Microbiology spectrum · 2026Article
- Emergence of ST1076 as a dominant high-risk clone carryingFrontiers in microbiology · 2026Article
- Integron architecture and virulence-associated gene profiles in extensively drug-resistant high-riskFrontiers in microbiology · 2026Article
- Genetic Analysis of Virulence and β-Lactamase Determinants Related to β-Lactamase Inhibitors inAntibiotics (Basel, Switzerland) · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A total of 3.180 nonduplicated Findings: A decrease in resistance to all tested antibiotics, including older and newer antimicrobials, was observed in 2022 vs 2017. Likewise, a major reduction of XDR (15.2% vs 5.9%) and DTR (4.2 vs 2.1%) profiles was evidenced, and even more patent among ICU isolates [XDR (26.0% vs 6.0%) and DTR (8.9% vs 2.6%)] (p < 0.001). The prevalence of Extended-spectrum β-lactamase/carbapenemase production was slightly lower in 2022 (2.1%. vs 3.1%, p = 0.064). However, there was a significant increase in the proportion of carbapenemase production among carbapenem-resistant strains (29.4% vs 18.1%, p = 0.0246). While ST175 was still the most frequent clone among XDR, a slight reduction in its prevalence was noted (35.9% vs 45.5%, p = 0.106) as opposed to ST235 which increased significantly (24.3% vs 12.3%, p = 0.0062). Interpretation: While the generalized decrease in Funding: MSD and the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.